 "vaccine")
As India's Covid-19 daily case count dips below the 100-mark, approvals for vaccines to be used as a mix-and-match dosing third shot are coming through. After Bharat Biotech's nasal vaccine got the nod as a heterologous booster for the Covishield and Covaxin two-dose primary regimen, it's the turn of Serum Institute of India's Covovax.
The Drugs Controller General of India (DCGI) has approved the market authorisation for SII's Covovax – the Novavax vaccine made in India – as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin. In 2022, the DCGI approved Cobevax,
